FDA Rejects Aldeyra’s Eye Cancer Injection, Citing Lack of Well-Controlled Studies
With no well-controlled data to support its efficacy, the FDA rejected Aldeyra’s methotrexate injection for primary vitreoretinal lymphoma.
FDA Rejects Aldeyra’s Eye Cancer Injection, Citing Lack of Well-Controlled Studies Read More »
